The mission of the HIV Prevention Trials Network (HPTN) is to discover and develop interventions that can be used globally to prevent sexual and/or parenteral transmission of HIV. Our research encompasses the testing of novel biomedical and behavioral approaches. We seek HIV prevention strategies that are effective, safe, feasible, and sustainable, even in resource-limited settings. The incumbent HPTN has built field site research capacity in 16 developing countries. In the International HIVNET and the HPTN, we have recruited 31,250 HIV uninfected (principally) and infected persons into 38 trials (19,500 by the incumbent HPTN since 1999). Subjects are almost exclusively high risk, including adolescents and acutely infected persons. Focusing on resource-constrained countries in Africa, Asia, So. America, and E. Europe, as well as high incidence populations in the U.S., our highest impact trials have literally changed global public health practice, as with HIVNET 012 for the prevention of mother-to-infant HIV transmission. We are dividing the current HPTN agenda into three parts, our perinatal group partnering to create IMPAACT and the microbicide group spearheading MTN. Hence, the new HPTN focus is fourfold: (1) antiretroviral therapy and co-infection therapy for viral load reduction and prevention of HIV transmission;(2) treatment of sexually transmitted infections (STI) to lower HIV transmission risk;(3) treatment of substance abuse and addiction, including injection drug use and stimulants (cocaine and methamphetamines) to reduce HIV transmission; and (4) behavioral risk reduction with biological endpoints. We use randomized controlled trials with HIV incidence endpoints in uninfected persons. For prevention research among acutely and chronically HIV- infected persons, we study incidence of non-HIV STIs, lowering of HIV viral load, and/or HIV incidence in sexual or needle-sharing partners. We propose to complete five ongoing HPTN trials and to transition an additional six ongoing HPTN trials to IMPAACT and MTN networks, if funded. We present eight new trial concepts, five for prevention of HIV infection, one for detection and intervention among acutely infected persons (pre-seroconversion), and two focused on prevention among HIV-seropositive persons. Our risk populations include high risk heterosexuals, men who have sex with men, substance abusers, and, for selected trials, their sexual or needle-sharing partners. Our proposed affiliated Clinical Trials Units serve at- risk populations on five continents, especially sub-Saharan Africa and the U.S. The HPTN Leadership Group is experienced and diverse and includes experienced ethics experts and community leaders. HPTN governance is designed to develop and complete trials efficiently. We emphasize concepts of high potential public health impact, focusing on existing technologies that can be brought immediately into practice. Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI068613-04
Application #
7643355
Study Section
Special Emphasis Panel (ZAI1-TH-A (J2))
Program Officer
Sharma, Usha K
Project Start
2006-06-01
Project End
2013-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
4
Fiscal Year
2009
Total Cost
$4,116,871
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Melendez, Johan H; Hardick, Justin; Barnes, Mathilda et al. (2018) Molecular Characterization of Markers Associated With Antimicrobial Resistance in Neisseria gonorrhoeae Identified From Residual Clinical Samples. Sex Transm Dis 45:312-315
Patel, Anuj V; Gaydos, Charlotte A; Jett-Goheen, Mary et al. (2018) Assessing association between IWantTheKit risk quiz tool and sexually transmitted infection positivity in male users for sexually transmitted infection screening. Int J STD AIDS 29:122-127
Patel, Anuj V; Abrams, Samuel M; Gaydos, Charlotte A et al. (2018) Increasing HIV testing engagement through provision of home HIV self-testing kits for patients who decline testing in the emergency department: a pilot randomisation study. Sex Transm Infect :
Holden, Jeffrey; Goheen, Joshua; Jett-Goheen, Mary et al. (2018) An evaluation of the SD Bioline HIV/syphilis duo test. Int J STD AIDS 29:57-62
Widdice, Lea E; Hsieh, Yu-Hsiang; Silver, Barbara et al. (2018) Performance of the Atlas Genetics Rapid Test for Chlamydia trachomatis and Women's Attitudes Toward Point-Of-Care Testing. Sex Transm Dis 45:723-727
Greer, Amy E; Ou, San-San; Wilson, Ethan et al. (2017) Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr 76:388-393
Bock, Peter; Phiri, Comfort; Piwowar-Manning, Estelle et al. (2017) Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. J Int AIDS Soc 20:21780
Gaydos, C A; Schwebke, J; Dombrowski, J et al. (2017) Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women. Expert Rev Mol Diagn 17:303-306
Jennings, Larissa; Pettifor, Audrey; Hamilton, Erica et al. (2017) Economic Resources and HIV Preventive Behaviors Among School-Enrolled Young Women in Rural South Africa (HPTN 068). AIDS Behav 21:665-677
Gaydos, Charlotte A; Klausner, Jeffrey D; Pai, Nitika Pant et al. (2017) Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men. Sex Transm Infect 93:S31-S35

Showing the most recent 10 out of 210 publications